Refining anti-inflammatory therapy strategies for bronchopulmonary dysplasia.

ABSTRACT: Bronchopulmonary dysplasia (BPD) is a severe lung disease of preterm infants, which is characterized by fewer, enlarged alveoli and increased inflammation. BPD has grave consequences for affected infants, but no effective and safe therapy exists. We previously showed that prophylactic treatment with interleukin-1 receptor antagonist (IL-1Ra) prevents murine BPD induced by perinatal inflammation and hyperoxia. Here, we used the same BPD model to assess whether an alternative anti-inflammatory agent, protein C (PC), is as effective as IL-1Ra against BPD. We also tested whether delayed administration or a higher dose of IL-1Ra affects its ability to ameliorate BPD and investigated aspects of drug safety. Pups were reared in room air (21% O₂ ) or hyperoxia (65% or 85% O₂

SUBMITTER: Rudloff I 

PROVIDER: S-EPMC5431131 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature